Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: A case-control study

N. L. Henry; D. Pchejetski; R. A'Hern; A. T. Nguyen; P. Charles; J. Waxman; L. Li; A. M. Storniolo; D. F. Hayes; D. A. Flockhart; V. Stearns; J. Stebbing

doi:10.1038/sj.bjc.6605768

Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: A case-control study

N. L. Henry, D. Pchejetski, R. A'Hern, A. T. Nguyen, P. Charles, J. Waxman, L. Li, A. M. Storniolo, D. F. Hayes, D. A. Flockhart, V. Stearns, J. Stebbing

Norwich Medical School

Research output: Contribution to journal › Article › peer-review

34 Citations (Scopus)

Abstract

The aromatase inhibitor (AI)-associated musculoskeletal syndrome (AIMSS) occurs in approximately 50% of AI-treated patients. Inflammatory mediators are associated with oestrogen signalling and may change with oestrogen depletion. We hypothesised that AIMSS may be associated with changes in circulating inflammatory markers.

Original language	English
Pages (from-to)	291-296
Number of pages	6
Journal	British Journal of Cancer
Volume	103
Issue number	3
Early online date	6 Jul 2010
DOIs	https://doi.org/10.1038/sj.bjc.6605768
Publication status	Published - 27 Jul 2010

Keywords

Aged
Androstadienes
Antineoplastic Agents
Aromatase Inhibitors
Breast Neoplasms
Bridged Compounds
Case-Control Studies
Cytokines
Estrogens
Female
Humans
Inflammation
Middle Aged
Musculoskeletal Diseases
Postmenopause
Syndrome
Tamoxifen
Taxoids

Access to Document

10.1038/sj.bjc.6605768Licence: CC BY-NC-SA

Cite this

@article{dd21c8a6720b4ce18ce602976a2a98b5,

title = "Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: A case-control study",

abstract = "The aromatase inhibitor (AI)-associated musculoskeletal syndrome (AIMSS) occurs in approximately 50% of AI-treated patients. Inflammatory mediators are associated with oestrogen signalling and may change with oestrogen depletion. We hypothesised that AIMSS may be associated with changes in circulating inflammatory markers.",

keywords = "Aged, Androstadienes, Antineoplastic Agents, Aromatase Inhibitors, Breast Neoplasms, Bridged Compounds, Case-Control Studies, Cytokines, Estrogens, Female, Humans, Inflammation, Middle Aged, Musculoskeletal Diseases, Postmenopause, Syndrome, Tamoxifen, Taxoids",

author = "Henry, {N. L.} and D. Pchejetski and R. A'Hern and Nguyen, {A. T.} and P. Charles and J. Waxman and L. Li and Storniolo, {A. M.} and Hayes, {D. F.} and Flockhart, {D. A.} and V. Stearns and J. Stebbing",

year = "2010",

month = jul,

day = "27",

doi = "10.1038/sj.bjc.6605768",

language = "English",

volume = "103",

pages = "291--296",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: A case-control study

AU - Henry, N. L.

AU - Pchejetski, D.

AU - A'Hern, R.

AU - Nguyen, A. T.

AU - Charles, P.

AU - Waxman, J.

AU - Li, L.

AU - Storniolo, A. M.

AU - Hayes, D. F.

AU - Flockhart, D. A.

AU - Stearns, V.

AU - Stebbing, J.

PY - 2010/7/27

Y1 - 2010/7/27

N2 - The aromatase inhibitor (AI)-associated musculoskeletal syndrome (AIMSS) occurs in approximately 50% of AI-treated patients. Inflammatory mediators are associated with oestrogen signalling and may change with oestrogen depletion. We hypothesised that AIMSS may be associated with changes in circulating inflammatory markers.

AB - The aromatase inhibitor (AI)-associated musculoskeletal syndrome (AIMSS) occurs in approximately 50% of AI-treated patients. Inflammatory mediators are associated with oestrogen signalling and may change with oestrogen depletion. We hypothesised that AIMSS may be associated with changes in circulating inflammatory markers.

KW - Aged

KW - Androstadienes

KW - Antineoplastic Agents

KW - Aromatase Inhibitors

KW - Breast Neoplasms

KW - Bridged Compounds

KW - Case-Control Studies

KW - Cytokines

KW - Estrogens

KW - Female

KW - Humans

KW - Inflammation

KW - Middle Aged

KW - Musculoskeletal Diseases

KW - Postmenopause

KW - Syndrome

KW - Tamoxifen

KW - Taxoids

U2 - 10.1038/sj.bjc.6605768

DO - 10.1038/sj.bjc.6605768

M3 - Article

C2 - 20606683

VL - 103

SP - 291

EP - 296

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 3

ER -